The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for game-changing treatments and significant returns is clear, the linked risks are also notable. Many of these